Dual anti-angiogenic and anti-metastatic activity of myriocin synergistically enhances the anti-tumor activity of cisplatin

Purpose Tumor microenvironment consists of various kind of cells, forming complex interactions and signal transductions for tumor growth. Due to this complexity, targeting multiple kinases could yield improved clinical outcomes. In this study, we aimed to investigate the potential of myriocin, from Mycelia sterilia, as a novel dual-kinase inhibitor and suggest myriocin as a candidate for combined chemotherapy. Methods We initially evaluated the anti-tumor and anti-metastatic effect of myriocin in mouse allograft tumor models. We examined the effects of myriocin on angiogenesis and tumor vasculature using in vitro, in vivo, and ex vivo models, and also tested the anti-migration effect of myriocin in in vitro models. Next, we explored the effects of myriocin alone and in combination with cisplatin on tumor growth and vascular normalization in mouse models. Results We found that myriocin inhibited tumor growth and lung metastasis in mouse allograft tumor models. Myriocin induced normalization of the tumor vasculature in the mouse models. We also found that myriocin suppressed angiogenesis through the VEGFR2/PI3K/AKT pathway in endothelial cells (ECs), as well as cancer cell migration by blocking the I kappa B alpha/NF-kappa B(p65)/MMP-9 pathway. Finally, we found that myriocin enhanced the drug delivery efficacy of cisplatin by increasing the integrity of tumor vasculature in the mouse models, which synergistically increased the anti-tumor activity of cisplatin. Conclusion We suggest that myriocin is a novel potent anti-cancer agent that dually targets both VEGFR2 in ECs and I kappa B alpha in cancer cells, and exerts more pronounced anti-tumor effects than with either kinase being inhibited alone.

Automated summary

The study showed that Avastin, a protease inhibitor, suppresses tumor growth and metastasis, as well as inhibits tumor dissemination by regulating angiogenesis and normalizing tumor vasculature. Additionally, Avastin was found to have inhibitory effects on the VEGFR2/PI3K/AKT pathway in endothelial cells of tumor vasculature, and on the I kappa B alpha/NF Kappa B(p65)/MMP-9 pathway in cancer cells, thereby suppressing their migration ability. Moreover, Avastin was found to enhance the integrity of tumor vasculature, improving the drug delivery efficacy of cisplatin and synergistically increasing its anti-tumor activity.